Amber List
XERS
Xeris Biopharma Holdings, Inc.
Healthcare · Biotechnology · small-cap ($1.0B)
-36.7%
from rolling 252-day high of $10.08 set 2025-11-05 · 190d ago
Current
$6.38
Decline depth
-36.7%
Decline σ
3.7σ
TFC
4/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Structural break signals

XERS qualifies for the Amber List on decline depth.

Decline depth
-36.7%
From rolling 252-day high of $10.08, 190d ago. Past the 30% Amber threshold.
Time-frame continuity
4/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3. Past the 4/5 Amber threshold.
Decline sigma
3.7σ
Drop from local high over the last 10 bars, expressed in units of the stock's typical daily volatility (2.82% per day).

The structural read

What price action says about XERS.

XERS qualifies for the Amber List on decline depth — down -36.7% from its rolling 252-day high.

Cross-confirmation: also showing 4/5 bearish time frames.

Upstream TFC read: weak alignment, current phase daily. Last bar types — daily 1 (red), weekly 2D (red), monthly 2U (green).

Earnings on file: 2026-03-02. Tiering is unaffected by earnings dates — listings reflect price structure only.

52-week range

52W low $3.81 41.0% of range 52W high $10.08

Sector context · Healthcare

182 other Healthcare tickers are on Broken Stocks.

93 Red List
42 Amber
47 Watch
-35.8% Median decline

Worst in sector: OPRX (-76.7%). Least-bad: ANIP (-20.0%). See all Healthcare listings →

Questions about XERS

What people ask.

Why is XERS on Broken Stocks?

XERS qualifies for the Amber List on decline depth. It is down -36.7% from its rolling 252-day high of $10.08, set on 2025-11-05 — 190d ago.

Is XERS a falling knife?

Not by the strict technical definition. XERS is down -36.7% from its 52-week high, but that high was set 190d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. XERS is still on the Amber List for decline depth, but the freshness component of a falling knife is missing.

Is XERS a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is XERS trading inside its 52-week range?

At $6.38, XERS sits 41.0% of the way from its 52-week low ($3.81) to its 52-week high ($10.08). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has XERS been declining?

The current 36.7% decline accrued over 190d, which annualizes to roughly -70.5% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does XERS compare to its sector?

There are 182 other Healthcare tickers on Broken Stocks: 93 Red, 42 Amber, 47 Watch, with 55 showing recovering structural signals. Median sector decline is -35.8% — XERS's decline is deeper than the sector median.

Does XERS's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-03-02) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.